GLP-1 medications have rapidly become some of the most influential treatments for Type 2 diabetes and weight loss. As more people look into these prescriptions, there is growing curiosity about how ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors.

This article originally appeared on PolitiFact. If you watch TV and don't mute ads, you've probably heard of a few biologics. They're drugs such as Humira for arthritis and Trulicity for Type 2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. GLP-1 use appears to be rising among patients with MASH ...

When diabetes causes CKD, it’s sometimes called diabetic kidney disease. Elevated blood sugar levels that result from diabetes can damage the tiny blood vessels inside your kidneys. As a result, your ...

The global GLP-1 market has been in the spotlight for the past couple of years as big pharma players realize its multi-billion-dollar potential and the untapped nature. It is currently dominated by ...

Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity in a real-world survey of certain US patients. Medicare patients who took ...

The duel of the GLP-1 data sets continues this week, with Novo issuing the latest salvo of updates on its oral obesity candidate and an Ozempic head-to-head trial win against another stalwart diabetes ...

Anyone who has worked with AI has experienced the moment when it feels like the system is ignoring you. You ask for one thing, get something else, and then wonder why it worked perfectly yesterday but ...

Mounjaro reduces major heart problems by 8% versus Trulicity in trial Death from any cause was 16% lower for patients on Mounjaro versus Trulicity Safety profile similar for both drugs July 31 ...

A trial of Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro fell short of expectations that it would do a better job of preventing heart attacks and strokes than its older medicine Trulicity. A ...